The following stories got
readers talking Wednesday:
A new study and upcoming conference are resurrecting the debate over whether cell phone user is tied to cancer.
Rich property investors from abroad are taking advantage of low prices and sluggish sales in the U.S.
shares are soaring, but their enterprise multiples suggest there are better values to be had in technology.
The FDA's cancer drug advisory panel voted 10-4 to recommend approval of Allos Therapeutics'
lymphoma drug pralatrexate.
will be in the spotlight on Wednesday, as investors consider whether the firm can earn its way out of the federal bailout and credit woes.
Follow TheStreet.com on
and become a fan on
This article was written by a staff member of TheStreet.com.